Lyell Immunopharma, Inc. (LYEL) Social Stream
LYELL IMMUNOPHARMA INC (LYEL) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering LYEL.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-15 | 3 | $25 | $22 | $24 | $1.99 | 1106.03% |
| 2022-01-06 | 3 | $22 | $20 | $20.666 | $1.99 | 938.49% |
| 2022-02-01 | 3 | $22 | $15 | $19 | $1.99 | 854.77% |
| 2022-03-30 | 3 | $20 | $15 | $16.666 | $1.99 | 737.49% |
| 2022-05-16 | 3 | $16 | $15 | $15.333 | $1.99 | 670.5% |
| 2022-07-15 | 4 | $16 | $12 | $14.333 | $1.99 | 620.25% |
| 2022-09-17 | 4 | $16 | $12 | $14.5 | $1.99 | 628.64% |
| 2022-10-17 | 5 | $16 | $12 | $14 | $1.99 | 603.52% |
| 2022-11-11 | 5 | $16 | $7 | $12.8 | $1.99 | 543.22% |
| 2022-11-14 | 5 | $14 | $7 | $9.75 | $1.99 | 389.95% |
| 2023-02-08 | 5 | $14 | $4 | $9 | $1.99 | 352.26% |
| 2023-03-03 | 5 | $14 | $4 | $8.5 | $1.99 | 327.14% |
| 2023-05-05 | 5 | $12 | $4 | $8 | $1.99 | 302.01% |
| 2023-05-09 | 5 | $10 | $4 | $7.5 | $1.99 | 276.88% |
| 2023-08-11 | 5 | $10 | $4.001 | $7.5 | $1.99 | 276.88% |
| 2023-08-28 | 5 | $10 | $4.001 | $7 | $1.99 | 251.76% |
| 2023-08-29 | 5 | $10 | $4 | $7 | $1.99 | 251.76% |
| 2023-09-30 | 5 | $10 | $4 | $6.8 | $1.99 | 241.71% |
| 2023-12-19 | 5 | $9 | $4 | $6.4 | $1.99 | 221.61% |
The Trend in the Analyst Price Target
LYEL's average price target has moved down $21.1 over the prior 30 months.
Over the past 47 weeks, LYEL's average upside potential has been 228.36%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-24 | 5 | 14 | 4 | 9.0 | 3.04 | 196.05% |
| 2023-02-08 | 5 | 14 | 4 | 9.0 | 3.08 | 192.21% |
| 2023-03-03 | 5 | 14 | 4 | 8.5 | 2.22 | 282.88% |
| 2023-05-09 | 5 | 10 | 4 | 7.5 | 2.47 | 203.64% |
| 2023-12-19 | 5 | 9 | 4 | 6.4 | 2.06 | 210.68% |
LYEL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.2 | 2 | 0 | 3 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
LYEL's average broker recommendation rating worsened by 0.87 over the prior 21 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how LYELL IMMUNOPHARMA INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1864.83% of that group.
- LYELL IMMUNOPHARMA INC's average analyst price target is greater than 286.23% of all US stocks.
- LYELL IMMUNOPHARMA INC's number of analysts covering the stock is higher than 320.18% of stocks in the mid market cap category.
- In the context of stocks in the mid market cap category, LYELL IMMUNOPHARMA INC's variance in analysts' estimates is lower than -999.62% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to LYELL IMMUNOPHARMA INC are AMLX, SWTX, and ALLO.
View All Top Stocks by Price Target
Is LYEL a Buy, Hold or Sell? See the POWR Ratings now!